50090-4202 : Eszopiclone 2 mg Oral Tablet, Film Coated


NDC: 50090-4202
Labeler: A-s Medication Solutions
Product Type: Human Prescription Drug
Drug Name:  Eszopiclone
Dosage Form: Oral Tablet, Film Coated
Application #: ANDA208451
Rev. Date: 
CSA Schedule: CIV (US) [1]


[1] Schedule IV Controlled Substance: Low potential for abuse relative to substances in Schedule III. Examples include Alprazolam (Xanax), Diazepam (Valium), Carisoprodol (Soma), Clonazepam (Klonopin), Lorazepam (Ativan), Clorazepate (Tranxene), Midazolam (Versed), Temazepam (Restoril), and Triazolam (Halcion).. More Details: US Dept of Justice Controlled Substance Schedules.

Appearance:


Markings: K;84
Shapes:  Round
Colors:  White
Size (mm): 6
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 50090-4202-0: 30 TABLET, FILM COATED IN 1 BOTTLE (50090‑4202‑0)

Active Ingredients:

  • Eszopiclone

Dosage Strength:

  • 2 mg

Inactive Ingredients:

  • Croscarmellose Sodium
  • Hypromellose 2910 (6 Mpa.s)
  • Lactose Monohydrate
  • Magnesium Stearate
  • Microcrystalline Cellulose
  • Polyethylene Glycol 3350
  • Titanium Dioxide
  • Triacetin /

Related Products:

Based on records with the same trade name.
  • 50090-1748 Eszopiclone 2 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-1899 Eszopiclone 1 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-2606 Eszopiclone 1 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-3514 Eszopiclone 3 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-3553 Eszopiclone 1 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-3989 Eszopiclone 1 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 50090-5084 Eszopiclone 3 mg Oral Tablet, Coated by A-s Medication Solutions
  • 50090-1457 Eszopiclone 2 mg Oral Tablet, Film Coated by A-s Medication Solutions LLC
  • 50090-1458 Eszopiclone 3 mg Oral Tablet, Film Coated by A-s Medication Solutions LLC
  • 54569-6609 Eszopiclone 1 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 54569-8804 Eszopiclone 2 mg Oral Tablet, Film Coated by A-s Medication Solutions
  • 0054-0290 Eszopiclone 1 mg Oral Tablet by Roxane Laboratories, Inc.
  • 0054-0291 Eszopiclone 2 mg Oral Tablet by Roxane Laboratories, Inc.
  • 0054-0292 Eszopiclone 3 mg Oral Tablet by Roxane Laboratories, Inc.
  • 0093-5537 Eszopiclone 1 mg Oral Tablet, Film Coated by Teva Pharmaceuticals USA Inc
  • 0093-5538 Eszopiclone 2 mg Oral Tablet, Film Coated by Teva Pharmaceuticals USA Inc
  • 0093-5539 Eszopiclone 3 mg Oral Tablet, Film Coated by Teva Pharmaceuticals USA Inc
  • 0378-5270 Eszopiclone 1 mg Oral Tablet, Film Coated by Mylan Pharmaceuticals Inc.
  • 0378-5271 Eszopiclone 2 mg Oral Tablet, Film Coated by Mylan Pharmaceuticals Inc.
  • 0378-5272 Eszopiclone 3 mg Oral Tablet, Film Coated by Mylan Pharmaceuticals Inc.
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 50090-4202 QR Code

< Prev: 50090-4201Next: 50090-4203 >

Related Discussions:

Eszopiclone (lunesta) Orange Tablets, no imprints
Small orange/peach round, uncoated pill from INDIA. No markings. They are supposed to be eszopisclone (generic lunesta).... 2 replies
Eszopiclone for old man (87 years old)
My father (87 years old) was consuming clonazepam for long time for sleep, around 1 year, and I think now he is resistan...
Side effects of eszopiclone manufactured by roxane
Are the side effects more common with the manufacturer Roxane versus Teva for the drug eszopiclone? ## No, it is still t... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.